Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrea Pirzkall"'
Autor:
Sophie Dalac-Rat, Anna Olsson-Brown, Jiaxin Niu, Praveen K. Bommareddy, Francesca Aroldi, Katy K. Tsai, Terence Duane Rhodes, Robert S. Coffin, Katharina C. Kähler, Adel Samson, Tawnya L. Bowles, Mohammed M. Milhem, Gino K. In, Bartosz Chmielowski, Eva Muñoz, Georgia M. Beasley, Joseph J. Sacco, Scott Baum, Kevin J. Harrington, Mark R. Middleton, Lavita Menezes, Hamid Emamekhoo, Jason Chesney, Andrea Pirzkall, Ari M. Vanderwalde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP1 is an enhanced potency oncolytic HSV-1 which expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM-CSF).1 In pre-clinical studies, RP1 demonstrated potent GALV-GP R-enhanced anti-tumor
Autor:
Pablo Nenclares, Praveen K. Bommareddy, Kevin J. Harrington, Anna Olsson-Brown, Henry Castro, Joseph J. Sacco, Tze Chan, Robert S. Coffin, Imran Saleem, Mark R. Middleton, Francesca Aroldi, Andrea Pirzkall, Isla Leslie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP2 is a first-in-class, enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being tested in an open-label, multicenter, phase 1 stu
Autor:
Claire F. Verschraegen, Susan Navia, Andrea Pirzkall, Andrew Poklepovic, Jason J. Luke, Frances A. Collichio, Praveen K. Bommareddy, Wanxing Chai-Ho, Diana Bolotin, Michael R. Migden, Robert S. Coffin, Henry Castro, Trisha Wise-Draper, Katy K. Tsai, Douglas Earl Laux, Gregory A. Daniels, Meenal Kheterpal, Jose Lutzky
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A580-A580
BackgroundSolid organ transplantation (SOT) has emerged as an important lifesaving procedure for patients with a wide range of end-organ diseases characterized by dysfunction or specific organ function failure. SOT rejection is a major complication r
Autor:
Mario R. Mautino, Ray S. Lin, John Edward Janik, Eugene P. Kennedy, Andrea Pirzkall, Charles J. Link, Xiaorong Liang, David H. Munn, Sami Mahrus, Bruce McCall, Nicholas N. Vahanian, Laurent Salphati, Zhonglin Hao, Stephanie Royer-Joo, Asha Nayak-Kapoor, Samir N. Khleif, Lisa Marshall, Ramses F. Sadek, W. Jay Ramsey, Kari M. Morrissey, Robin Dobbins
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i